Vutrisiran Treatment and Cardiovascular MRI-Detected Changes in Cardiac Structure, Function, and Amyloid Burden in ATTR-CM

MedXY Editorial Team•Aug 18, 2026•Cardiology

Vutrisiran therapy leads to significant improvements in biventricular systolic function and reductions in left ventricular mass in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
Cardiovascular magnetic resonance (CMR) imaging with extracellular volume (ECV) mapping enables sensitive, noninvasive tracking of cardiac amyloid burden and treatment-related regression.
Post hoc analysis of the UK HELIOS-B cohort demonstrates that vutrisiran associates with amyloid regression in a subset of patients and markedly reduces amyloid progression compared to placebo over three years.
Echocardiographic secondary outcomes corroborate structural and functional cardiac benefits, underscoring vutrisiran’s impact on clinical outcomes.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Vutrisiran therapy leads to significant improvements in biventricular systolic function and reductions in left ventricular mass in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
Cardiovascular magnetic resonance (CMR) imaging with extracellular volume (ECV) mapping enables sensitive, noninvasive tracking of cardiac amyloid burden and treatment-related regression.
Post hoc analysis of the UK HELIOS-B cohort demonstrates that vutrisiran associates with amyloid regression in a subset of patients and markedly reduces amyloid progression compared to placebo over three years.
Echocardiographic secondary outcomes corroborate structural and functional cardiac benefits, underscoring vutrisiran’s impact on clinical outcomes.